Biocon shares in focus after Malaysia unit gets clearance from the USFDA

Brokerage firm Jefferies had upgraded Biocon last week to “hold” from its earlier rating of “underperform” and raised its price target to ₹400 from ₹280 earlier.

Leave a Reply

Your email address will not be published. Required fields are marked *